Amir Ronen co-founded Sensible Medical Innovations in 2007 with the aim of bringing top notch technology innovations to the area of heart failure care.

Prior to founding Sensible Medical, he served as the vice president in two NASDAQ traded companies (NSDQ: FLSH, SFUN) and played a leading role in the strategy planning at Intel Corporation (NSDQ: INTC).

Amir holds a B.Sc. in Electrical Engineering from the Technion – Israel Institute of Technology, and an MBA from the Kellogg (Northwestern University)-Recanati (Tel-Aviv University) International Executive MBA program.

Edward Rosen is the founder and managing partner of Glendevon Life Sciences. He is a serial entrepreneur with a foundation of success in multinational drug, device and diagnostic companies and extensive experience out-licensing technology from academic institutions. Ed is currently an Executive-in-Residence for the Technology Ventures Group at Columbia University and was the founding CEO, President, Chief Executive Officer and a Director of Elucida Oncology, Inc. Ed has more than 25 years of operational and leadership experience in the life sciences industry, including Worldwide Vice President of Marketing for a large division of Johnson & Johnson. Ed attended the University of Lincoln in the UK, receiving a BA with honors in Business.

The Glendevon strategy will seek to generate long-term capital appreciation by leveraging an exceptional team to found and make venture capital investments in life science companies – including biotechnology, pharmaceutical, diagnostics and medical devices.

We do this by bridging academic research and Series A investment by:

• Establishing exclusive licensing of early-stage life science intellectual property, prioritizing probability-of-success as an investment philosophy.
• Targeting quality niche opportunities less attractive to larger funds due to scale.
• Defining realizable and affordable milestones to enable strong Series A fundraising potential.
• Supplying high-talent Management Service Team to enhance performance of Portfolio Companies and tailor leadership to early-stage company needs.

Performance 

Prior team successes include founding/co-founding and/or senior executive and scientific leadership for Lodo Therapeutics, Elucida Oncology, Bioleap, Revolution Medicine, Arcellx, NKarta Therapeutics, Cell Therapy Accelerator, Battersea Biotech, InFocus Capital Partners, Equitable and Alliance Capital Partners, International Fund Administration and Sierra Global Management.

 

Yubo is the founder of 8 Decimal Capital, a multinational investment firm in the blockchain industry. He is also the Co-founder of Skylight Investment, a Boston-based venture fund backed by New Oriental (NYSE:EDU). Before his career in venture capital, Yubo founded Alisimba, which was later acquired by TopHacker Group. He currently holds 5 patents and was nominated for AACYF’s 30 under 30 in 2017.

 

Christina Bechhold Russ is a Principal at Samsung NEXT Ventures, based in New York, focused on early stage investments in software and services, particularly in mobility, consumer IoT and fintech. She is also Co-Founder and Managing Director of Empire Angels, a member led angel group of young professionals investing in technology startups with a focus on supporting young entrepreneurs. Christina is a Regular Contributor for the Wall Street Journal on startups and small business, a columnist for Inc.com, a mentor at The Brandery and Venture for America and a member of VFA’s Rise Committee focused on increasing diversity in entrepreneurship. She is a frequent speaker and panelist at events in the U.S., Europe and Asia, a TEDx speaker, and was recognized by the New York Business Journal as a 2016 Woman of Influence.

 

Heads the US offices for Stable Asset Management, a hedge fund seeding business focused on specialist strategies.

Responsibilities include manager origination, talent acquisition,strategic and business development, investor relations and distribution.

Over 30 years of investment advisory, capital markets and prime brokerage experience including Managing Director and Head of Prime Brokerage at Lazard cm, Senior roles at Barclays Private Bank and Royal Bank of Canada, beginning his career at Bear Stearns in commodity arbitrage.

Graduate of Tufts University with a BA in Soviet and Eastern European Studies.